Publications by authors named "Matthew Wikler"

Claim this Profile
S
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
G Ralph Corey, Jeffery Loutit, Greg Moeck, Matthew Wikler, Michael N Dudley

Antimicrob Agents Chemother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.
G Ralph Corey, Francis F Arhin, Matthew A Wikler, Daniel F Sahm, Barry N Kreiswirth

Int J Antimicrob Agents· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler

Infect Dis Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler

Infect Dis Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
G Ralph Corey, Samantha Good, Hai Jiang, Greg Moeck, Matthew Wikler

Clin Infect Dis· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zabofloxacin (DW-224a) activity against Neisseria gonorrhoeae including quinolone-resistant strains.
Ronald N Jones, Douglas J Biedenbach, Paul G Ambrose, Matthew A Wikler

Diagn Microbiol Infect Dis· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction of a reference to clinical laboratory standards institute interpretive criteria.
Matthew A Wikler, Mary Jane Ferraro

Clin Infect Dis· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
Nathan C Dean, Paul Sperry, Matthew Wikler, Mary S Suchyta, Carol Hadlock

Antimicrob Agents Chemother· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
Sujata M Bhavnani, Jeffrey P Hammel, Brenda B Cirincione, Matthew A Wikler, Paul G Ambrose

Antimicrob Agents Chemother· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
Yunhua Chen, Elizabeth Garber, Qiuqu Zhao, Yigong Ge, Matthew A Wikler

Antimicrob Agents Chemother· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro antimicrobial activity of doripenem, a new carbapenem.
Yigong Ge, Matthew A Wikler, Daniel F Sahm, Renée S Blosser-Middleton, James A Karlowsky

Antimicrob Agents Chemother· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
Lawrence D Sher, Michael D Poole, Kristen Von Seggern, Matthew A Wikler, Susan C Nicholson

Otolaryngol Head Neck Surg· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
Mark Gotfried, Thomas C Quinn, Samantha Gothelf, Matthew A Wikler, C Douglas Webb

Diagn Microbiol Infect Dis· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
Antonio Anzueto, Mark Gotfried, Matthew A Wikler, Rene Russo, Susan C Nicholson

Clin Ther· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis